1.Male or female subjects of 18 years to 60 years age (both inclusive) <br/ >2.Subject and/or his/her legally accepted representative willing to give written informed consent. <br/ >3.Subjects with laboratory confirmation of infection with SARS-CoV-2 by positive RT-PCR (within 48 hours prior to randomization). <br/ >4.Subjects having moderate COVID-19 as per MoH & FW guidelines on â??Clinical Management Protocol: COVID-19â?? as updated from time to time. <br/ >o Moderate COVID-19: Pneumonia with no signs of severe disease, with presence of clinical features of dyspnoea and or hypoxia, fever, cough, including SpO2 â?¤93% (range 90-93%) on room air, respiratory rate more or equal to 24 per minute. (Time for symptom onset and baseline should be no more than 10 days). <br/ >

1.Male or female subjects of 18 years to 60 years age (both inclusive) <br/ >2.Subject and/or his/her legally accepted representative willing to give written informed consent. <br/ >3.Subjects with laboratory confirmation of infection with SARS-CoV-2 by positive RT-PCR (within 48 hours prior to randomization). <br/ >4.Subjects having moderate COVID-19 as per MoH & FW guidelines on â??Clinical Management Protocol: COVID-19â?? as updated from time to time. <br/ >o Moderate COVID-19: Pneumonia with no signs of severe disease, with presence of clinical features of dyspnoea and or hypoxia, fever, cough, including SpO2 â?¤93% (range 90-93%) on room air, respiratory rate more or equal to 24 per minute. (Time for symptom onset and baseline should be no more than 10 days). <br/ >

1.Male or female subjects of 18 years to 60 years age (both inclusive) <br/ >2.Subject and/or his/her legally accepted representative willing to give written informed consent. <br/ >3.Subjects with laboratory confirmation of infection with SARS-CoV-2 by positive RT-PCR (within 48 hours prior to randomization). <br/ >4.Subjects having moderate COVID-19 as per MoH & FW guidelines on â??Clinical Management Protocol: COVID-19â?? as updated from time to time. <br/ >o Moderate COVID-19: Pneumonia with no signs of severe disease, with presence of clinical features of dyspnoea and or hypoxia, fever, cough, including SpO2 â?¤93% (range 90-93%) on room air, respiratory rate more or equal to 24 per minute. (Time for symptom onset and baseline should be no more than 10 days). <br/ >

1.Male or female subjects of 18 years to 60 years age (both inclusive) <br/ >2.Subject and/or his/her legally accepted representative willing to give written informed consent. <br/ >3.Subjects with laboratory confirmation of infection with SARS-CoV-2 by positive RT-PCR (within 48 hours prior to randomization). <br/ >4.Subjects having moderate COVID-19 as per MoH & FW guidelines on â??Clinical Management Protocol: COVID-19â?? as updated from time to time. <br/ >o Moderate COVID-19: Pneumonia with no signs of severe disease, with presence of clinical features of dyspnoea and or hypoxia, fever, cough, including SpO2 â?¤93% (range 90-93%) on room air, respiratory rate more or equal to 24 per minute. (Time for symptom onset and baseline should be no more than 10 days). <br/ >